Cargando…
Metformin Synergistically Potentiates the Antitumor Effects of Imatinib in Colorectal Cancer Cells
Metformin is the most commonly prescribed anti-diabetic drug with relatively minor side effect. Substantial evidence has suggested that metformin is associated with decreased cancer risk and anticancer activity against diverse cancer cells. The tyrosine kinase inhibitor imatinib has shown powerful a...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The Korean Society of Developmental Biology
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5532306/ https://www.ncbi.nlm.nih.gov/pubmed/28785735 http://dx.doi.org/10.12717/DR.2017.21.2.139 |